A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease

  • Ezra A. Amsterdam
    Requests for reprints should be addressed to Ezra A. Amsterdam, MD, Division of Cardiovascular Medicine, 4150 V Street, Suite 3500, Sacramento, California 95817
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of California (Davis) Medical Center, Sacramento, California, USA

    Cardiology Division, Department of Medicine, University of California San Francisco School of Medicine, San Francisco, California, USA
    Search for articles by this author
  • Prakash C. Deedwania
    Stanford University Medical Center, Palo Alto, California, USA
    Search for articles by this author


      The clinical benefits of lowering elevated serum cholesterol for both primary and secondary prevention of coronary artery disease are now well established. Reduction in clinical events occurs early and appears to be related to stabilization of atherosclerotic plaque. Despite these salutary findings, lipid-lowering therapy, both nondrug and pharmacologic, is still markedly underutilized in patients and high-risk individuals in the asymptomatic population. Recent practical and uncomplicated guidelines present a rational strategy for selection of patients for low-density lipoprotein (LDL) cholesterol reduction and have the potential to yield major clinical benefits if properly implemented. Preventive cardiology measures should be applied by matching the intensity of the intervention to the hazard for clinical events. We support the current guidelines of the expert panels described in this article and propose several extensions for cholesterol lowering in selected, high-risk populations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Deedwania P.C.
        Clinical perspectives on primary and secondary prevention of coronary atherosclerosis.
        Med Clin North Am. 1995; 79: 973-998
        • Brown M.S.
        • Goldstein J.L.
        Heart attacks.
        Science. 1996; 272 (Editorial): 629
        • Pearson T.A.
        • McBride P.E.
        • Miller N.H.
        • Smith S.C.
        Task Force 8.
        J Am Coll Cardiol. 1996; 27: 1039-1047
      1. Heart and Stroke Facts: 1997 Statistical Supplement. Dallas, TX: American Heart Association; 1997.

      2. Fact Book Fiscal Year 1997. Bethesda, MD: National Heart, Lung, and Blood Institute; 1997.

        • Pekkanen J.
        • Linn S.
        • Heiss G.
        • et al.
        Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.
        N Engl J Med. 1990; 322: 1700-1707
        • Amsterdam E.A.
        • Hyson D.
        • Kappagoda C.T.
        Nonpharmacologic therapy for coronary artery atherosclerosis.
        Am Heart J. 1994; 128: 1344-1352
        • Lewis B.
        • Watts G.F.
        Paradise regained.
        J Royal Coll Phys. 1997; 31: 263-275
        • Merz C.N.B.
        • Rozanski A.
        • Forrester J.S.
        The secondary prevention of coronary artery disease.
        Am J Med. 1997; 102: 572-581
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
        Lancet. 1994; 344: 1383-1389
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Stone N.J.
        The clinical and economic significance of atherosclerosis.
        Am J Med. 1996; 101: 6S-9S
        • Faxon D.P.
        Introduction and historical background.
        in: Faxon D.P. Practical Angioplasty. Raven Press, New York1994: 1-5
        • Takaro T.
        • Pifarre R.
        • Fish R.
        Left main coronary artery disease.
        Prog Cardiovasc Dis. 1985; 28: 229-234
        • Passamani E.
        • Davis K.B.
        • Gillespie M.J.
        • et al.
        A randomized trial of coronary artery bypass surgery.
        N Engl J Med. 1985; 312: 1665-1671
        • Forrester J.S.
        • Shah P.K.
        Lipid lowering versus revascularization.
        Circulation. 1997; 96: 1360-1362
        • Pilote L.
        • Califf R.M.
        • Sapp S.
        • et al.
        Regional variation across the United States in the management of acute myocardial infarction.
        N Engl J Med. 1995; 333: 565-572
        • Pilote L.
        • Miller D.P.
        • Califf R.M.
        • et al.
        Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction.
        N Engl J Med. 1996; 335: 1198-1205
        • Reeder G.S.
        Identification and management of the low-risk patient after myocardial infarction.
        ACC Current J Rev. 1997; 6: 27-31
        • Deedwania P.C.
        • Amsterdam E.A.
        • Vagelos R.H.
        • et al.
        Evidence-based, cost-effective risk stratification and management after myocardial infarction.
        Arch Intern Med. 1997; 157: 273-280
        • Falk E.
        • Shah P.K.
        • Fuster V.
        Coronary plaque disruption.
        Circulation. 1995; 92: 657-671
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Waters D.
        Plaque stabilization.
        Progress in Cardiovas Dis. 1994; 37: 107-120
        • Nakagomi A.
        • Celermajer D.S.
        • Lumley T.
        • Freedman S.B.
        Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis.
        Am J Cardiol. 1996; 78: 516-519
        • Superko H.R.
        • Krauss R.M.
        Coronary artery disease regression.
        Circulation. 1994; 90: 1056-1069
        • Brown B.G.
        • Zhao X.-Q.
        • Sacco D.E.
        • Albers J.J.
        Lipid lowering and plaque regression.
        Circulation. 1993; 87: 1781-1791
        • The Post Coronary Artery Bypass Graft Trial Investigators
        The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
        N Engl J Med. 1997; 336: 153-162
        • National Cholesterol Education Program
        Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
        Circulation. 1994; 89: 1329-1445
        • Ashraf T.
        • Hay J.W.
        • Pitt B.
        • et al.
        Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
        Am J Cardiol. 1996; 78: 409-414
        • Johannesson M.
        • Jönsson B.
        • Kjekshus J.
        • et al.
        Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease.
        N Engl J Med. 1997; 336: 332-336
        • Eichstädt H.W.
        • Eskotter H.
        • Hoffman I.
        • et al.
        Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
        Am J Cardiol. 1995; 76: 122A-125A
        • van Boven A.J.
        • Jukema J.W.
        • Zwinderman A.H.
        • et al.
        Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris.
        Circulation. 1996; 94: 1503-1505
        • Andrews T.C.
        • Raby K.
        • Barry J.
        • et al.
        Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease.
        Circulation. 1997; 95: 324-328
        • O’Driscoll G.
        • Green D.
        • Taylor R.R.
        Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.
        Circulation. 1997; 95: 1126-1131
        • Crouse III, J.R.
        • Byington R.P.
        • Hoen H.M.
        • Furberg C.D.
        Reductase inhibitor monotherapy and stroke prevention.
        Ann Intern Med. 1997; 157: 1305-1310
        • Amsterdam E.A.
        Epidemiologic studies of diet and drug therapy to reach target LDL-C levels.
        Am J Managed Care. 1996; 2: 25S-30S
        • Swan H.J.C.
        • Gersh B.J.
        • Graboys T.B.
        • Ullyot D.J.
        Task Force 7.
        J Am Coll Cardiol. 1996; 27: 1030-1039
        • Smith Jr, S.C.
        • Blair S.N.
        • Criqui M.H.
        • et al.
        Preventing heart attack and death in patients with coronary disease.
        Circulation. 1995; 92: 2-4
        • Grundy S.M.
        • Balady G.J.
        • Criqui M.H.
        • et al.
        Guide to primary prevention of cardiovascular diseases.
        Circulation. 1997; 95: 2329-2331
      3. Fuster V, Pearson TA, co-chairs. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:957–1047.

        • Grundy S.M.
        • Balady G.J.
        • Criqui M.H.
        • et al.
        When to start cholesterol-lowering therapy in patients with coronary heart disease.
        Circulation. 1997; 95: 1683-1685